Publication | Closed Access

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Neck CancerPhase Ii TrialSuberoylanilide Hydroxamic AcidMedicinePharmacologyHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyCancer Research